Back
  1. Home
  2. Profile of Martyna SZPAKOWSKA (Unilu)
Profil

SZPAKOWSKA Martyna

University of Luxembourg

Main Referenced Co-authors
Chevigné, Andy (3)
NICLOU, Simone  (3)
MEYRATH, Max Marc Roger  (2)
NAZAROV, Petr  (2)
Neirinckx, Virginie (2)
Main Referenced Keywords
AXL (2); EGFR (2); Humans (2); NanoBiT (2); 42HK56048U (Tyrosine) (1);
Main Referenced Disciplines
Oncology (3)
Neurology (1)
Biochemistry, biophysics & molecular biology (1)

Publications (total 5)

The most downloaded
79 downloads
Meyrath, M., Szpakowska, M., Plesseria, J.-M., Domingues, O., Langlet, J., Weber, B., Krüger, R., Ollert, M., & Chevigné, A. (09 September 2022). Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples. Methods in Enzymology, 675, 351-381. doi:10.1016/bs.mie.2022.07.015 https://hdl.handle.net/10993/54409

The most cited

62 citations (Scopus®)

Reynders, Abboud, Baragli, Noman, Rogister, NICLOU, S. P., Heveker, JANJI, B., Hanson, SZPAKOWSKA, M., & Chevigné. (June 2019). The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 8 (6), 613. doi:10.3390/cells8060613 https://hdl.handle.net/10993/60437

Neirinckx, V., Hau, A.-C., Schuster, A., FRITAH, S., Tiemann, K., KLEIN, E., NAZAROV, P., Matagne, A., SZPAKOWSKA, M., MEYRATH, M. M. R., Chevigné, A., Schmidt, M. H. H., & NICLOU, S. P. (2024). The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma. Neuro-Oncology Advances, 1 (1), 024. doi:10.1093/noajnl/vdz024
Peer Reviewed verified by ORBi

Largeot, A., Klapp, V., Viry, E., Gonder, S., Fernandez Botana, I., Blomme, A., BENZARTI, M., Pierson, S., Duculty, C., Marttila, P., Wierz, M., Gargiulo, E., Pagano, G., An, N., El Hachem, N., Perez Hernandez, D., Chakraborty, S., Ysebaert, L., François, J.-H., ... MOUSSAY, E.*. (29 June 2023). Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL. Blood, 141 (26), 3166 - 3183. doi:10.1182/blood.2022017839
Peer Reviewed verified by ORBi
* These authors have contributed equally to this work.

Dosquet, H., Neirinckx, V., MEYRATH, M. M. R., Wantz, M., HAAN, S., NICLOU, S. P., SZPAKOWSKA, M., & Chevigné, A. (2023). Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). In Chapter One - Nanoluciferase-based complementation assays to monitor activation, modulation and signaling of receptor tyrosine kinases (RTKs). Elsevier. doi:10.1016/bs.mie.2022.09.002
Peer Reviewed verified by ORBi

Meyrath, M., Szpakowska, M., Plesseria, J.-M., Domingues, O., Langlet, J., Weber, B., Krüger, R., Ollert, M., & Chevigné, A. (09 September 2022). Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples. Methods in Enzymology, 675, 351-381. doi:10.1016/bs.mie.2022.07.015
Peer Reviewed verified by ORBi

Reynders, Abboud, Baragli, Noman, Rogister, NICLOU, S. P., Heveker, JANJI, B., Hanson, SZPAKOWSKA, M., & Chevigné. (June 2019). The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment. Cells, 8 (6), 613. doi:10.3390/cells8060613
Peer Reviewed verified by ORBi

Contact ORBilu